Edwards Lifesciences Corp
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, and
CONSOLIDATED BALANCE SHEETS
(in millions, except par value)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $3,045.2 | $1,132.3 |
| Short-term investments (Note 8) | 930.7 | 500.5 |
| Accounts receivable, net of allowances of $11.6 and $8.2, respectively | 609.1 | 771.5 |
| Other receivables | 118.3 | 56.6 |
| Inventories (Note 6) | 1,086.7 | 903.5 |
| Prepaid expenses | 121.0 | 128.8 |
| Other current assets | 347.6 | 224.9 |
| Current assets of discontinued operations (Note 5) | 26.8 | 317.6 |
| Total current assets | 6,285.4 | 4,035.7 |
| Long-term investments (Note 8) | 307.9 | 583.9 |
| Property, plant, and equipment, net (Note 6) | 1,686.0 | 1,591.0 |
| Operating lease right-of-use assets (Note 7) | 98.2 | 84.4 |
| Goodwill (Note 11) | 1,776.7 | 1,145.1 |
| Other intangible assets, net (Note 11) | 1,176.6 | 399.4 |
| Deferred income taxes | 992.1 | 749.4 |
| Other assets | 721.6 | 463.2 |
| Non-current assets of discontinued operations (Note 5) | 10.8 | 311.1 |
| Total assets | $13,055.3 | $9,363.2 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities | ||
| Accounts payable | $197.4 | $186.6 |
| Accrued and other liabilities (Note 6) | 1,282.4 | 856.4 |
| Operating lease liabilities (Note 7) | 23.4 | 22.9 |
| Current liabilities of discontinued operations (Note 5) | 2.0 | 129.5 |
| Total current liabilities | 1,505.2 | 1,195.4 |
| Long-term debt (Note 12) | 597.7 | 597.0 |
| Contingent consideration liabilities (Note 13) | 14.5 | — |
| Taxes payable (Note 19) | 1.3 | 80.6 |
| Operating lease liabilities (Note 7) | 78.9 | 65.2 |
| Uncertain tax positions (Note 19) | 384.6 | 335.0 |
| Litigation settlement accrual (Note 3) | 52.7 | 94.2 |
| Other liabilities | 357.5 | 251.3 |
| Non-current liabilities of discontinued operations (Note 5) | — | 25.1 |
| Total liabilities | 2,992.4 | 2,643.8 |
| Commitments and contingencies (Notes 7, 12, and 20) | ||
| Stockholders' equity (Note 16) | ||
| Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding | — | — |
| Common stock, $1.00 par value, 1,050.0 shares authorized, 654.8 and 650.5 shares issued, and 588.6 and 601.1 shares outstanding, respectively | 654.8 | 650.5 |
| Additional paid-in capital | 2,613.4 | 2,274.4 |
| Retained earnings | 13,167.0 | 8,992.4 |
| Accumulated other comprehensive loss (Note 17) | (244.5) | (242.8) |
| Treasury stock, at cost, 66.2 and 49.4 shares, respectively | (6,192.3) | (5,024.5) |
| Total Edwards Lifesciences Corporation stockholders' equity | 9,998.4 | 6,650.0 |
| Noncontrolling interest | 64.5 | 69.4 |
| Total stockholders' equity | 10,062.9 | 6,719.4 |
| Total liabilities and equity | $13,055.3 | $9,363.2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.